Acetylsalicylic acid:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Berlin
De Gruyter dup
[2022]
|
| Ausgabe: | 3rd edition |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XII, 630 Seiten Illustrationen, Diagramme 24 cm x 17 cm |
| ISBN: | 9783110745726 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV048461179 | ||
| 003 | DE-604 | ||
| 005 | 20221006 | ||
| 007 | t | ||
| 008 | 220908s2022 a||| |||| 00||| eng d | ||
| 015 | |a 22,N06 |2 dnb | ||
| 016 | 7 | |a 1250851882 |2 DE-101 | |
| 020 | |a 9783110745726 |c : EUR 159.95 (DE) (freier Preis), EUR 159.95 (AT) (freier Preis) |9 978-3-11-074572-6 | ||
| 035 | |a (OCoLC)1347218212 | ||
| 035 | |a (DE-599)DNB1250851882 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-83 | ||
| 084 | |a VT 5000 |0 (DE-625)147738: |2 rvk | ||
| 084 | |a 540 |2 sdnb | ||
| 100 | 1 | |a Schrör, Karsten |d 1942- |e Verfasser |0 (DE-588)120284472 |4 aut | |
| 245 | 1 | 0 | |a Acetylsalicylic acid |c Karsten Schrör |
| 250 | |a 3rd edition | ||
| 264 | 1 | |a Berlin |b De Gruyter dup |c [2022] | |
| 264 | 4 | |c © 2022 | |
| 300 | |a XII, 630 Seiten |b Illustrationen, Diagramme |c 24 cm x 17 cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 0 | 7 | |a Pharmakologie |0 (DE-588)4045687-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Acetylsalicylsäure |0 (DE-588)4000351-6 |2 gnd |9 rswk-swf |
| 653 | |a Toxikologie | ||
| 653 | |a Pharmakologie | ||
| 653 | |a Arzneimittel | ||
| 653 | |a Organische Chemie | ||
| 653 | |a Drug, Organic chemistry, Pharmacology, Toxicology | ||
| 689 | 0 | 0 | |a Acetylsalicylsäure |0 (DE-588)4000351-6 |D s |
| 689 | 0 | 1 | |a Pharmakologie |0 (DE-588)4045687-0 |D s |
| 689 | 0 | |5 DE-604 | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe |z 9783110746488 |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe |z 9783110746419 |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033839178&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-033839178 | ||
Datensatz im Suchindex
| _version_ | 1804184402936201216 |
|---|---|
| adam_text | CONTENTS
PREFACE
-
V
1
GENERAL
ASPECTS
-
1
1.1
HISTORY
-----
1
1.1.1
FROM
WILLOW
BARK
TO
SALICYLIC
ACID
-----
9
1.1.1.1
ANTIINFLAMMATORY
AND
ANALGESIC
EFFECTS
OF
WILLOW
BARK
----
9
1.1.1.2
SALICYLATES
AS
THE
ACTIVE
INGREDIENTS
OF
WILLOW
BARK
AND
OTHER
NATURAL
SOURCES
-----
10
1.1.1.3
CHEMICAL
SYNTHESIS
OF
SALICYLIC
ACID
----
10
1.1.2
SYNTHESIS
OF
ACETYLATED
SALICYLIC
ACID
(ASPIRIN)
AND
FIRST
MEDICAL
USE
-----
13
1.1.2.1
THE
INVENTION
OF
ACETYLATED
SALICYLIC
ACID
-----
13
1.1.2.2
INTRODUCTION
OF
ACETYLSALICYLIC
ACID
IN
THE
CLINIC
-----
20
1.1.3
SEARCH
FOR
PHARMACOLOGICAL
MODES
OF
ASPIRIN
ACTION
----
23
1.1.3.1
SALICYLATES
AND
ENERGY
METABOLISM
OF
THE
CELL
-----
24
1.1.3.2
INHIBITION
OF
CYCLOOXYGENASES
BY
SALICYLATES
-----
25
1.1.3.3
FURTHER
ACTIONS
OF
SALICYLATES
ON
CELL
SIGNALING
-----
30
1.1.4
CLINICAL
APPLICATIONS
-
A
PIECE
OF
HISTORY
-----
34
1.1.4.1
ANTIINFLAMMATORY/ANALGESIC
AND
ANTIPYRETIC
ACTIONS
-----
34
1.1.4.2
ANTIPLATELET/ANTITHROMBOTIC
ACTIONS
AND
BLEEDING
-----
35
1.1.4.3
ASPIRIN
AND
THE
HISTORY
OF
PREVENTION
OF
MYOCARDIAL
INFARCTION
AND
STROKE
----
37
1.1.4.4
ASPIRIN
AND
TUMOR
PREVENTION
-----
41
1.1.5
CURRENT
RESEARCH
TOPICS
------44
1.1.5.1
CLINICAL
RESEARCH
-----
44
1.1.5.2
BASIC
RESEARCH
-----
45
1.2
CHEMISTRY
------49
1.2.1
STRUCTURES
AND
CHEMICAL
PROPERTIES
OF
SALICYLATES
-----
50
1.2.1.1
SALICYLATES
IN
CLINICAL
USE
-
CHEMICAL
PROPERTIES
-----
51
1.2.1.2
ASPIRIN
FORMULATIONS
-----
53
1.2.2
DETERMINATION
OF
SALICYLATES
-----
56
1.2.2.1
GENERAL
ASPECTS
-----
56
1.2.2.2
METHODS
OF
DETERMINATION
-----
57
2
PHARMACOLOGY
----
61
2.1
PHARMACOKINETICS
-----
62
2.1.1
ABSORPTION
AND
DISTRIBUTION
-------
63
2.1.1.1
ABSORPTION
AND
BIOAVAILABILITY
---
63
2.1.1.2
ASPIRIN
FORMULATIONS
AND
APPLICATION
MODES
66
2.1.1.3
DISTRIBUTION
AND
PLASMA
LEVELS
----
71
VIII
-
CONTENTS
2.1.1.4
MODIFYING
FACTORS
-----
73
2.1.2
BIOTRANSFORMATION
AND
EXCRETION
------
77
2.1.2.1
BIOTRANSFORMATIONS
OF
ASPIRIN
------
77
2.1.2.2
BIOTRANSFORMATIONS
OF
SALICYLIC
ACID
-----
81
2.1.2.3
EXCRETION
OF
SALICYLATES
-----
83
2.2
CELLULAR
MODES
OF
ACTION
-----
87
2.2.1
INHIBITION
OF
CYCLOOXYGENASES
------
89
2.2.1.1
GENERAL
ASPECTS
-
89
2.2.1.2
INHIBITION/MODULATION
OF
CYCLOOXYGENASES
BY
ASPIRIN
----
91
2.2.1.3
THE
DIFFERENT
PHARMACOLOGY
OF
ASPIRIN
AND
NSAIDS----
98
2.2.1.4
FURTHER
ACTIONS
OF
SALICYLATES
ON
LIPID
MEDIATORS
----
100
2.2.2
COX-INDEPENDENT
ACTIONS
OF
ASPIRIN
ON
CELL
FUNCTION
----
104
2.2.2.1
GENERAL
ASPECTS
----
104
2.2.2.2
SALICYLATES
IN
THE
PLANT
KINGDOM
-----
105
2.2.2.3
NON-COX
ACETYLATION
ACTIONS
OF
ASPIRIN
-----
106
2.2.2.4
ASPIRIN
AND
NITRIC
OXIDE
FORMATION
-----
106
2.2.2.5
SALICYLATESAND
KINASES
-----
109
2.2.2.6
SALICYLATES
AND
TRANSCRIPTION
FACTORS
-
113
2.2.3
ENERGY
METABOLISM
-----
119
2.2.3.1
GENERAL
ASPECTS
-
119
2.2.3.2
SALICYLATES
AND
FATTY
ACID
P-OXIDATION
-----
121
2.2.3.3
SALICYLATES
AND
UNCOUPLING
OF
OXIDATIVE
PHOSPHORYLATION
-
125
2.2.3.4
METABOLIC
ACTIONS
OF
SALICYLATES
AND
REYE S
SYNDROME
-
128
2.3
ACTIONS
ON
ORGANS
AND
TISSUES
----
133
2.3.1
HEMOSTASIS
AND
THROMBOSIS
-----
134
2.3.1.1
GENERAL
ASPECTS
------
134
2.3.1.2
PLATELETS
-----
137
2.3.1.3
ENDOTHELIAL
CELLS
-----
145
2.3.1.4
PLASMATIC
COAGULATION
-----
150
2.3.1.5
FIBRINOLYSIS
-----
150
2.3.2
INFLAMMATION,
MICROBIAL
INFECTIONS,
PAIN
AND
FEVER
-
160
2.3.2.1
GENERAL
ASPECTS
------
160
2.3.2.2
MODES
OF
ANTIINFLAMMATORY
ACTIONS
OF
ASPIRIN
-----
162
2.3.2.3
MODES
OF
ANTIMICROBIAL
ACTIONS
OF
ASPIRIN
-----
170
2.3.2.4
MODES
OF
ANALGESIC
ACTIONS
OF
ASPIRIN
-----
172
2.3.2.5
MODES
OF
ANTIPYRETIC
ACTIONS
OF
ASPIRIN
-----
177
2.3.3
ASPIRIN
AND
MALIGNANCIES
-----
185
2.3.3.1
GENERAL
ASPECTS
-----
185
2.3.3.2
PATHOPHYSIOLOGY
OF
INTESTINAL
NEOPLASIAS
-----
187
2.3.3.3
MODESOF
ASPIRIN
ACTION
-----
191
2.3.3.4
COX-RELATED
ACTIONS
OF
ASPIRIN
-----
192
2.3.3.5
NON-COX-RELATED
ANTITUMOR
ACTIONS
OF
ASPIRIN
-----
196
CONTENTS
-
IX
3
TOXICITY
AND
DRUG
SAFETY
----
207
3.1
SYSTEMIC
SIDE
EFFECTS
-----
208
3.1.1
ACUTE
AND
CHRONIC
TOXICITY
----
209
3.1.1.1
GENERAL
ASPECTS
-----
209
3.1.1.2
PATHOPHYSIOLOGY
AND
CLINICAL
SYMPTOMS
OF
ACUTE
TOXICITY
-----
211
3.1.1.3
PATHOPHYSIOLOGY
AND
CLINICAL
SYMPTOMS
OF
CHRONIC
TOXICITY
-----
214
3.
1.1.4
TREATMENT
-----
215
3.1.1.5
HABITUATION
-----
216
3.1.2
BLEEDING
TIME
AND
BLEEDING
RISK
-----
221
3.1.2.1
GENERAL
ASPECTS
-----
221
3.1.2.2
BLEEDINGTIME
-----
221
3.1.2.3
MODES
OF
ASPIRIN
ACTION
-----
225
3.1.2.4
ASPIRIN-RELATED
BLEEDING
IN
LONG-TERM
PREVENTION
----
227
3.1.2.5
ASPIRIN-RELATED
BLEEDING
IN
SURGERY
AND
WITHDRAWAL
----
228
3.1.2.6
PREVENTION
AND
TREATMENT
OF
BLEEDING
-----
230
3.1.3
SAFETY
PHARMACOLOGY
IN
PARTICULAR
LIFE
SITUATIONS
----
237
3.1.3.1
GENERAL
ASPECTS
----
237
3.1.3.2
PREGNANCY
AND
FETAL
DEVELOPMENT
-----
237
3.1.3.3
THE
ELDERLY
PATIENT
----
241
3.2
ORGAN
TOXICITY
-----
248
3.2.1
GASTROINTESTINAL
TRACT
----
248
3.2.1.1
GENERAL
ASPECTS
-----
248
3.2.1.2
PATHOPHYSIOLOGY
OF
GASTROINTESTINAL
(STOMACH)
INJURY
----
249
3.2.1.3
MODES
OF
ASPIRIN
ACTION
-
252
3.2.1.4
CLINICAL
STUDIES
-----
258
3.2.1.5
ASPIRIN
AND
OTHER
DRUGS
-
262
3.2.2
LIVER
-----
269
3.2.2.1
GENERAL
ASPECTS
-----
269
3.2.2.2
PATHOPHYSIOLOGY
AND
MODE
OF
ASPIRIN
ACTION
-----
270
3.2.2.3
CLINICAL
STUDIES
------
270
3.2.3
KIDNEY
AND
HEART
FAILURE
-----
273
3.2.3.1
GENERAL
ASPECTS
-----
273
3.2.3.2
MODE
OF
ASPIRIN
ACTION
-----
274
3.2.3.3
CLINICAL
STUDIES
-
INDIVIDUALS
WITHOUT
KIDNEY
DISEASES
------
275
3.2.3.4
CLINICAL
STUDIES
-
INDIVIDUALS
WITH
PREEXISTING
KIDNEY
DISEASES
-----
276
3.2.3.5
HEART
FAILURE
--------
279
3.2.4
AUDIOVESTIBULAR
SYSTEM
----
284
3.2.4.1
GENERAL
ASPECTS
-----
284
3.2.4.2
PATHOPHYSIOLOGY
OF
ASPIRIN-INDUCED
HEARING
LOSS
-----
285
3.2.4.3
CLINICAL
STUDIES
--------
287
3.3
HYPERSENSITIVITY
TO
ASPIRIN
AND
REYE
S
SYNDROME
----
291
X
-
CONTENTS
3.3.1
ASPIRIN-EXACERBATED
RESPIRATORY
DISEASE
(
ASPIRIN-INDUCED
ASTHMA,
WIDAL
SYNDROME)
-
292
3.3.1.1
HISTORY
AND
EPIDEMIOLOGY
-----
292
3.3.1.2
PATHOPHYSIOLOGY
OF
AERD
-----
293
3.3.1.3
MODE
OF
ASPIRIN
ACTION
-
297
3.3.1.4
CLINICAL
STUDIES
-----
299
3.3.1.5
ASPIRIN
AND
OTHER
DRUGS
-----
301
3.3.2
URTICARIA/ANGIOEDEMA,
STEVENS-JOHNSON
SYNDROME
AND
LYELL
SYNDROME
-
306
3.3.2.1
URTICARIA/ANGIOEDEMA
-----
306
3.3.2.2
STEVENS-JOHNSON
SYNDROME
AND
LYELL
SYNDROME
-----
307
3.3.3
REYE
S
SYNDROME
-----
309
3.3.3.1
HISTORY
AND
EPIDEMIOLOGY
------
309
3.3.3.2
CLINICS,
LABORATORY
AND
MORPHOLOGICAL
FINDINGS
-----
311
3.3.3.3
ETIOLOGY
AND
PATHOGENESIS
------
313
3.3.3.4
CLINICAL
STUDIES
-----
316
3.3.3.5
ACTUAL
SITUATION
-----
323
4
CLINICAL
APPLICATIONS
OF
ASPIRIN
-
331
4.1
THROMBOEMBOLIC
DISEASES
-----
337
4.1.1
CORONARY
VASCULAR
DISEASE
-
338
4.1.1.1
GENERAL
ASPECTS
-----
338
4.1.1.2
THROMBOTIC
RISK
AND
MODE
OF
ASPIRIN
ACTION
-----
340
4.1.1.3
CLINICAL
TRIALS
-
PRIMARY
PREVENTION
IN
APPARENTLY
HEALTHY
INDIVIDUALS
344
4.1.1.4
CLINICAL
TRIALS
-
PRIMARY
PREVENTION
IN
INDIVIDUALS
WITH
VASCULAR
RISK
FACTORS
353
4.1.1.5
CLINICAL
TRIALS
-
PRIMARY
PREVENTION
IN
PATIENTS
WITH
DIABETES
-----
357
4.1.1.6
CLINICAL
TRIALS
-
PATIENTS
WITH
CHRONIC
CORONARY
VASCULAR
DISEASE
-
362
4.1.1.7
CLINICAL
TRIALS
-
PATIENTS
WITH
ACUTE
CORONARY
SYNDROME
(ACS)
-----
363
4.1.1.8
CLINICAL
TRIALS
-
LONG-TERM
SECONDARY
PREVENTION
-----
367
4.1.1.9
CLINICAL
TRIALS
-
CORONARY
ARTERY
BYPASS
GRAFT
SURGERY
AND
OTHER
SURGICAL
INTERVENTIONS
373
4.1.1.10
ASPIRIN
AND
OTHER
DRUGS
----
376
4.1.1.11
ACTUAL
SITUATION
-----
390
4.1.2
CEREBROVASCULAR
DISEASES
-----
409
4.1.2.1
GENERAL
ASPECTS
-----
409
4.1.2.2
THROMBOTIC
RISK
AND
MODE
OF
ASPIRIN
ACTION
-----
411
4.1.2.3
CLINICAL
TRIALS
-
PRIMARY
PREVENTION
-----
415
4.1.2.4
CLINICAL
TRIALS
-
SECONDARY
PREVENTION
----
416
4.1.2.5
ASPIRIN
AND
OTHER
DRUGS
------
424
4.1.2.6
ACTUAL
SITUATION
-----
435
CONTENTS
-----
XI
4.1.3
PERIPHERAL
ARTERIAL
OCCLUSIVE
DISEASE
-----
445
4.1.3.1
GENERAL
ASPECTS
-----
445
4.1.3.2
THROMBOTIC
RISK
AND
MODE
OF
ASPIRIN
ACTION
-----
447
4.1.3.3
CLINICAL
TRIALS:
PRIMARY
PREVENTION
-----
449
4.1.3.4
CLINICAL
TRIALS:
SECONDARY
PREVENTION
-----
451
4.1.3.5
CLINICAL
TRIALS:
PERIPHERAL
TRANSLUMINAL
ANGIOPLASTY
-----
452
4.1.3.6
ASPIRIN
AND
OTHER
DRUGS
-----
454
4.1.3.7
ACTUAL
SITUATION
-----
457
4.1.4
VENOUS
THROMBOEMBOLISM
------
461
4.1.4.1
GENERAL
ASPECTS
-
461
4.1.4.2
THROMBOTIC
RISK
AND
MODES
OF
ASPIRIN
ACTION
-----
464
4.1.4.3
CLINICAL
TRIALS
-
PRIMARY
PREVENTION
-----
464
4.1.4.4
CLINICAL
TRIALS
-
SECONDARY
PREVENTION
-----
471
4.1.4.5
ASPIRIN
AND
OTHER
DRUGS
-
NOACS
--------
473
4.1.4.6
ACTUAL
SITUATION
------
474
4.1.5
PREGNANCY-INDUCED
HYPERTENSION
(PREECLAMPSIA)
AND
PRETERM
DELIVERY
----
479
4.1.5.1
GENERAL
ASPECTS
------
479
4.1.5.2
VASCULAR
RISK
AND
MODES
OF
ASPIRIN
ACTION
----
481
4.1.5.3
CLINICAL
TRIALS
-----
486
4.1.5.4
CLINICAL
TRIALS
-
REASONS
FOR
DATA
VARIABILITY
----
488
4.1.5.5
ACTUAL
SITUATION
-----
492
4.1.6
ASPIRIN
HIGH
ON
TREATMENT
PLATELET
REACTIVITY
(HTPR,
ASPIRIN
RESISTANCE)
-
500
4.1.6.1
GENERAL
ASPECTS
-----
500
4.1.6.2
DEFINITION
AND
TYPES
OF
ASPIRIN
-
HTPR
----
501
4.1.6.3
DETECTION
OF
ASPIRIN
HTPR
----
504
4.1.6.4
MECHANISMS
OF
ASPIRIN
HTPR
------
507
4.1.6.5
CLINICAL
TRIALS
-----
515
4.1.6.6
ACTUAL
SITUATION
-----
519
4.2
PAIN,
FEVER
AND
INFLAMMATORY
DISEASES
-----
528
4.2.1
ANALGESIA
AND
ANTIPYRESIS
-----
529
4.2.1.1
GENERAL
ASPECTS
-----
529
4.2.1.2
PAIN,
FEVER
AND
MODE
OF
ANALGESIC/ANTIPYRETIC
ASPIRIN
ACTION
----
530
4.2.1.3
CLINICAL
TRIALS
-----
534
4.2.1.4
ASPIRIN
AND
OTHER
DRUGS
-----
538
4.2.1.5
ACTUAL
SITUATION
-----
539
4.2.2
INFLAMMATORY
DISEASES
AND
VIRAL
INFECTIONS
----
542
4.2.2.1
GENERAL
ASPECTS
-----
542
4.2.2.2
RHEUMATOID
ARTHRITIS
-
PATHOPHYSIOLOGY,
MODE
OF
ASPIRIN
ACTION
AND
CLINICAL
TRIALS
-----
544
XII
-
-
CONTENTS
4.2.2.3
OSTEOARTHRITIS
-
PATHOPHYSIOLOGY,
MODE
OF
ASPIRIN
ACTION
AND
CLINICAL
TRIALS
-----
547
4.2.2.4
SYSTEMIC
INFLAMMATORY
RESPONSE
SYNDROME
(SIRS).
PATHOPHYSIOLOGY,
MODE
OF
ASPIRIN
ACTION
AND
CLINICAL
TRIALS.
SEPSIS
AND
ACUTE
RESPIRATORY
DISTRESS
SYNDROME
(ARDS)
-----
548
4.2.2.5
HIV
-
PATHOPHYSIOLOGY,
MODE
OF
ASPIRIN
ACTION
AND
CLINICAL
TRIALS
-----
552
4.2.2.6
COVID-19
AND
FLU-LIKE
CONDITIONS:
PATHOPHYSIOLOGY,
MODES
OF
ASPIRIN
ACTION
AND
CLINICAL
TRIALS
555
4.2.2.7
ASPIRIN
AND
OTHER
DRUGS
-----
559
4.2.2.8
ACTUAL
SITUATION
-----
560
4.2.3
KAWASAKI
DISEASE
------
567
4.2.3.1
GENERAL
ASPECTS
------
567
4.2.3.2
PATHOPHYSIOLOGY
AND
MODE
OF
ASPIRIN
ACTION
-----
568
4.2.3.3
CLINICAL
TRIALS
-----
569
4.2.3.4
ASPIRIN
AND
OTHER
DRUGS
-----
571
4.2.3.5
ACTUAL
SITUATION
-----
571
4.3
FURTHER
POTENTIAL
CLINICAL
INDICATIONS
------
574
4.3.1
COLORECTAL
TUMORS
(ADENOMAS,
CARCINOMAS)
------
575
4.3.1.1
GENERAL
ASPECTS
-----
575
4.3.1.2
EPIDEMIOLOGY,
ETIOLOGY
AND
PATHOGENESIS
----
576
4.3.1.3
MODES
OF
ASPIRIN
ACTION
----
578
4.3.1.4
CLINICAL
TRIALS
-
PRIMARY
PREVENTION
----
581
4.3.1.5
CLINICAL
TRIALS
-
SECONDARY
PREVENTION
----
587
4.3.1.6
ASPIRIN
AND
OTHER
DRUGS
-----
593
4.3.1.7
ACTUAL
SITUATION
-----
594
4.3.2
ALZHEIMER
S
DISEASE
AND
OTHER
NEUROLOGICAL
DISORDERS
----
602
4.3.
2.1 GENERAL
ASPECTS
-----
602
4.3.2.2
EPIDEMIOLOGY,
ETIOLOGY
AND
PATHOPHYSIOLOGY
-----
602
4.3.2.3
MODES
OF
ASPIRIN
ACTION
-----
603
4.3.2.4
CLINICAL
TRIALS
-----
605
4.3.2.5
ASPIRIN
AND
OTHER
DRUGS
-----
609
4.3.2.6
ACTUAL
SITUATION
-----
609
ABBREVIATIONS
----
613
ACRONYMS
OF
CLINICAL
TRIALS
-
617
INDEX
----
623
|
| adam_txt |
CONTENTS
PREFACE
-
V
1
GENERAL
ASPECTS
-
1
1.1
HISTORY
-----
1
1.1.1
FROM
WILLOW
BARK
TO
SALICYLIC
ACID
-----
9
1.1.1.1
ANTIINFLAMMATORY
AND
ANALGESIC
EFFECTS
OF
WILLOW
BARK
----
9
1.1.1.2
SALICYLATES
AS
THE
ACTIVE
INGREDIENTS
OF
WILLOW
BARK
AND
OTHER
NATURAL
SOURCES
-----
10
1.1.1.3
CHEMICAL
SYNTHESIS
OF
SALICYLIC
ACID
----
10
1.1.2
SYNTHESIS
OF
ACETYLATED
SALICYLIC
ACID
(ASPIRIN)
AND
FIRST
MEDICAL
USE
-----
13
1.1.2.1
THE
INVENTION
OF
ACETYLATED
SALICYLIC
ACID
-----
13
1.1.2.2
INTRODUCTION
OF
ACETYLSALICYLIC
ACID
IN
THE
CLINIC
-----
20
1.1.3
SEARCH
FOR
PHARMACOLOGICAL
MODES
OF
ASPIRIN
ACTION
----
23
1.1.3.1
SALICYLATES
AND
ENERGY
METABOLISM
OF
THE
CELL
-----
24
1.1.3.2
INHIBITION
OF
CYCLOOXYGENASES
BY
SALICYLATES
-----
25
1.1.3.3
FURTHER
ACTIONS
OF
SALICYLATES
ON
CELL
SIGNALING
-----
30
1.1.4
CLINICAL
APPLICATIONS
-
A
PIECE
OF
HISTORY
-----
34
1.1.4.1
ANTIINFLAMMATORY/ANALGESIC
AND
ANTIPYRETIC
ACTIONS
-----
34
1.1.4.2
ANTIPLATELET/ANTITHROMBOTIC
ACTIONS
AND
BLEEDING
-----
35
1.1.4.3
ASPIRIN
AND
THE
HISTORY
OF
PREVENTION
OF
MYOCARDIAL
INFARCTION
AND
STROKE
----
37
1.1.4.4
ASPIRIN
AND
TUMOR
PREVENTION
-----
41
1.1.5
CURRENT
RESEARCH
TOPICS
------44
1.1.5.1
CLINICAL
RESEARCH
-----
44
1.1.5.2
BASIC
RESEARCH
-----
45
1.2
CHEMISTRY
------49
1.2.1
STRUCTURES
AND
CHEMICAL
PROPERTIES
OF
SALICYLATES
-----
50
1.2.1.1
SALICYLATES
IN
CLINICAL
USE
-
CHEMICAL
PROPERTIES
-----
51
1.2.1.2
ASPIRIN
FORMULATIONS
-----
53
1.2.2
DETERMINATION
OF
SALICYLATES
-----
56
1.2.2.1
GENERAL
ASPECTS
-----
56
1.2.2.2
METHODS
OF
DETERMINATION
-----
57
2
PHARMACOLOGY
----
61
2.1
PHARMACOKINETICS
-----
62
2.1.1
ABSORPTION
AND
DISTRIBUTION
-------
63
2.1.1.1
ABSORPTION
AND
BIOAVAILABILITY
---
63
2.1.1.2
ASPIRIN
FORMULATIONS
AND
APPLICATION
MODES
66
2.1.1.3
DISTRIBUTION
AND
PLASMA
LEVELS
----
71
VIII
-
CONTENTS
2.1.1.4
MODIFYING
FACTORS
-----
73
2.1.2
BIOTRANSFORMATION
AND
EXCRETION
------
77
2.1.2.1
BIOTRANSFORMATIONS
OF
ASPIRIN
------
77
2.1.2.2
BIOTRANSFORMATIONS
OF
SALICYLIC
ACID
-----
81
2.1.2.3
EXCRETION
OF
SALICYLATES
-----
83
2.2
CELLULAR
MODES
OF
ACTION
-----
87
2.2.1
INHIBITION
OF
CYCLOOXYGENASES
------
89
2.2.1.1
GENERAL
ASPECTS
-
89
2.2.1.2
INHIBITION/MODULATION
OF
CYCLOOXYGENASES
BY
ASPIRIN
----
91
2.2.1.3
THE
DIFFERENT
PHARMACOLOGY
OF
ASPIRIN
AND
NSAIDS----
98
2.2.1.4
FURTHER
ACTIONS
OF
SALICYLATES
ON
LIPID
MEDIATORS
----
100
2.2.2
COX-INDEPENDENT
ACTIONS
OF
ASPIRIN
ON
CELL
FUNCTION
----
104
2.2.2.1
GENERAL
ASPECTS
----
104
2.2.2.2
SALICYLATES
IN
THE
PLANT
KINGDOM
-----
105
2.2.2.3
NON-COX
ACETYLATION
ACTIONS
OF
ASPIRIN
-----
106
2.2.2.4
ASPIRIN
AND
NITRIC
OXIDE
FORMATION
-----
106
2.2.2.5
SALICYLATESAND
KINASES
-----
109
2.2.2.6
SALICYLATES
AND
TRANSCRIPTION
FACTORS
-
113
2.2.3
ENERGY
METABOLISM
-----
119
2.2.3.1
GENERAL
ASPECTS
-
119
2.2.3.2
SALICYLATES
AND
FATTY
ACID
P-OXIDATION
-----
121
2.2.3.3
SALICYLATES
AND
UNCOUPLING
OF
OXIDATIVE
PHOSPHORYLATION
-
125
2.2.3.4
METABOLIC
ACTIONS
OF
SALICYLATES
AND
REYE'S
SYNDROME
-
128
2.3
ACTIONS
ON
ORGANS
AND
TISSUES
----
133
2.3.1
HEMOSTASIS
AND
THROMBOSIS
-----
134
2.3.1.1
GENERAL
ASPECTS
------
134
2.3.1.2
PLATELETS
-----
137
2.3.1.3
ENDOTHELIAL
CELLS
-----
145
2.3.1.4
PLASMATIC
COAGULATION
-----
150
2.3.1.5
FIBRINOLYSIS
-----
150
2.3.2
INFLAMMATION,
MICROBIAL
INFECTIONS,
PAIN
AND
FEVER
-
160
2.3.2.1
GENERAL
ASPECTS
------
160
2.3.2.2
MODES
OF
ANTIINFLAMMATORY
ACTIONS
OF
ASPIRIN
-----
162
2.3.2.3
MODES
OF
ANTIMICROBIAL
ACTIONS
OF
ASPIRIN
-----
170
2.3.2.4
MODES
OF
ANALGESIC
ACTIONS
OF
ASPIRIN
-----
172
2.3.2.5
MODES
OF
ANTIPYRETIC
ACTIONS
OF
ASPIRIN
-----
177
2.3.3
ASPIRIN
AND
MALIGNANCIES
-----
185
2.3.3.1
GENERAL
ASPECTS
-----
185
2.3.3.2
PATHOPHYSIOLOGY
OF
INTESTINAL
NEOPLASIAS
-----
187
2.3.3.3
MODESOF
ASPIRIN
ACTION
-----
191
2.3.3.4
COX-RELATED
ACTIONS
OF
ASPIRIN
-----
192
2.3.3.5
NON-COX-RELATED
ANTITUMOR
ACTIONS
OF
ASPIRIN
-----
196
CONTENTS
-
IX
3
TOXICITY
AND
DRUG
SAFETY
----
207
3.1
SYSTEMIC
SIDE
EFFECTS
-----
208
3.1.1
ACUTE
AND
CHRONIC
TOXICITY
----
209
3.1.1.1
GENERAL
ASPECTS
-----
209
3.1.1.2
PATHOPHYSIOLOGY
AND
CLINICAL
SYMPTOMS
OF
ACUTE
TOXICITY
-----
211
3.1.1.3
PATHOPHYSIOLOGY
AND
CLINICAL
SYMPTOMS
OF
CHRONIC
TOXICITY
-----
214
3.
1.1.4
TREATMENT
-----
215
3.1.1.5
HABITUATION
-----
216
3.1.2
BLEEDING
TIME
AND
BLEEDING
RISK
-----
221
3.1.2.1
GENERAL
ASPECTS
-----
221
3.1.2.2
BLEEDINGTIME
-----
221
3.1.2.3
MODES
OF
ASPIRIN
ACTION
-----
225
3.1.2.4
ASPIRIN-RELATED
BLEEDING
IN
LONG-TERM
PREVENTION
----
227
3.1.2.5
ASPIRIN-RELATED
BLEEDING
IN
SURGERY
AND
WITHDRAWAL
----
228
3.1.2.6
PREVENTION
AND
TREATMENT
OF
BLEEDING
-----
230
3.1.3
SAFETY
PHARMACOLOGY
IN
PARTICULAR
LIFE
SITUATIONS
----
237
3.1.3.1
GENERAL
ASPECTS
----
237
3.1.3.2
PREGNANCY
AND
FETAL
DEVELOPMENT
-----
237
3.1.3.3
THE
ELDERLY
PATIENT
----
241
3.2
ORGAN
TOXICITY
-----
248
3.2.1
GASTROINTESTINAL
TRACT
----
248
3.2.1.1
GENERAL
ASPECTS
-----
248
3.2.1.2
PATHOPHYSIOLOGY
OF
GASTROINTESTINAL
(STOMACH)
INJURY
----
249
3.2.1.3
MODES
OF
ASPIRIN
ACTION
-
252
3.2.1.4
CLINICAL
STUDIES
-----
258
3.2.1.5
ASPIRIN
AND
OTHER
DRUGS
-
262
3.2.2
LIVER
-----
269
3.2.2.1
GENERAL
ASPECTS
-----
269
3.2.2.2
PATHOPHYSIOLOGY
AND
MODE
OF
ASPIRIN
ACTION
-----
270
3.2.2.3
CLINICAL
STUDIES
------
270
3.2.3
KIDNEY
AND
HEART
FAILURE
-----
273
3.2.3.1
GENERAL
ASPECTS
-----
273
3.2.3.2
MODE
OF
ASPIRIN
ACTION
-----
274
3.2.3.3
CLINICAL
STUDIES
-
INDIVIDUALS
WITHOUT
KIDNEY
DISEASES
------
275
3.2.3.4
CLINICAL
STUDIES
-
INDIVIDUALS
WITH
PREEXISTING
KIDNEY
DISEASES
-----
276
3.2.3.5
HEART
FAILURE
--------
279
3.2.4
AUDIOVESTIBULAR
SYSTEM
----
284
3.2.4.1
GENERAL
ASPECTS
-----
284
3.2.4.2
PATHOPHYSIOLOGY
OF
ASPIRIN-INDUCED
HEARING
LOSS
-----
285
3.2.4.3
CLINICAL
STUDIES
--------
287
3.3
HYPERSENSITIVITY
TO
ASPIRIN
AND
REYE
'
S
SYNDROME
----
291
X
-
CONTENTS
3.3.1
ASPIRIN-EXACERBATED
RESPIRATORY
DISEASE
(
"
ASPIRIN-INDUCED
ASTHMA,
"
WIDAL
SYNDROME)
-
292
3.3.1.1
HISTORY
AND
EPIDEMIOLOGY
-----
292
3.3.1.2
PATHOPHYSIOLOGY
OF
AERD
-----
293
3.3.1.3
MODE
OF
ASPIRIN
ACTION
-
297
3.3.1.4
CLINICAL
STUDIES
-----
299
3.3.1.5
ASPIRIN
AND
OTHER
DRUGS
-----
301
3.3.2
URTICARIA/ANGIOEDEMA,
STEVENS-JOHNSON
SYNDROME
AND
LYELL
SYNDROME
-
306
3.3.2.1
URTICARIA/ANGIOEDEMA
-----
306
3.3.2.2
STEVENS-JOHNSON
SYNDROME
AND
LYELL
SYNDROME
-----
307
3.3.3
REYE
'
S
SYNDROME
-----
309
3.3.3.1
HISTORY
AND
EPIDEMIOLOGY
------
309
3.3.3.2
CLINICS,
LABORATORY
AND
MORPHOLOGICAL
FINDINGS
-----
311
3.3.3.3
ETIOLOGY
AND
PATHOGENESIS
------
313
3.3.3.4
CLINICAL
STUDIES
-----
316
3.3.3.5
ACTUAL
SITUATION
-----
323
4
CLINICAL
APPLICATIONS
OF
ASPIRIN
-
331
4.1
THROMBOEMBOLIC
DISEASES
-----
337
4.1.1
CORONARY
VASCULAR
DISEASE
-
338
4.1.1.1
GENERAL
ASPECTS
-----
338
4.1.1.2
THROMBOTIC
RISK
AND
MODE
OF
ASPIRIN
ACTION
-----
340
4.1.1.3
CLINICAL
TRIALS
-
PRIMARY
PREVENTION
IN
APPARENTLY
HEALTHY
INDIVIDUALS
344
4.1.1.4
CLINICAL
TRIALS
-
PRIMARY
PREVENTION
IN
INDIVIDUALS
WITH
VASCULAR
RISK
FACTORS
353
4.1.1.5
CLINICAL
TRIALS
-
PRIMARY
PREVENTION
IN
PATIENTS
WITH
DIABETES
-----
357
4.1.1.6
CLINICAL
TRIALS
-
PATIENTS
WITH
CHRONIC
CORONARY
VASCULAR
DISEASE
-
362
4.1.1.7
CLINICAL
TRIALS
-
PATIENTS
WITH
ACUTE
CORONARY
SYNDROME
(ACS)
-----
363
4.1.1.8
CLINICAL
TRIALS
-
LONG-TERM
SECONDARY
PREVENTION
-----
367
4.1.1.9
CLINICAL
TRIALS
-
CORONARY
ARTERY
BYPASS
GRAFT
SURGERY
AND
OTHER
SURGICAL
INTERVENTIONS
373
4.1.1.10
ASPIRIN
AND
OTHER
DRUGS
----
376
4.1.1.11
ACTUAL
SITUATION
-----
390
4.1.2
CEREBROVASCULAR
DISEASES
-----
409
4.1.2.1
GENERAL
ASPECTS
-----
409
4.1.2.2
THROMBOTIC
RISK
AND
MODE
OF
ASPIRIN
ACTION
-----
411
4.1.2.3
CLINICAL
TRIALS
-
PRIMARY
PREVENTION
-----
415
4.1.2.4
CLINICAL
TRIALS
-
SECONDARY
PREVENTION
----
416
4.1.2.5
ASPIRIN
AND
OTHER
DRUGS
------
424
4.1.2.6
ACTUAL
SITUATION
-----
435
CONTENTS
-----
XI
4.1.3
PERIPHERAL
ARTERIAL
OCCLUSIVE
DISEASE
-----
445
4.1.3.1
GENERAL
ASPECTS
-----
445
4.1.3.2
THROMBOTIC
RISK
AND
MODE
OF
ASPIRIN
ACTION
-----
447
4.1.3.3
CLINICAL
TRIALS:
PRIMARY
PREVENTION
-----
449
4.1.3.4
CLINICAL
TRIALS:
SECONDARY
PREVENTION
-----
451
4.1.3.5
CLINICAL
TRIALS:
PERIPHERAL
TRANSLUMINAL
ANGIOPLASTY
-----
452
4.1.3.6
ASPIRIN
AND
OTHER
DRUGS
-----
454
4.1.3.7
ACTUAL
SITUATION
-----
457
4.1.4
VENOUS
THROMBOEMBOLISM
------
461
4.1.4.1
GENERAL
ASPECTS
-
461
4.1.4.2
THROMBOTIC
RISK
AND
MODES
OF
ASPIRIN
ACTION
-----
464
4.1.4.3
CLINICAL
TRIALS
-
PRIMARY
PREVENTION
-----
464
4.1.4.4
CLINICAL
TRIALS
-
SECONDARY
PREVENTION
-----
471
4.1.4.5
ASPIRIN
AND
OTHER
DRUGS
-
NOACS
--------
473
4.1.4.6
ACTUAL
SITUATION
------
474
4.1.5
PREGNANCY-INDUCED
HYPERTENSION
(PREECLAMPSIA)
AND
PRETERM
DELIVERY
----
479
4.1.5.1
GENERAL
ASPECTS
------
479
4.1.5.2
VASCULAR
RISK
AND
MODES
OF
ASPIRIN
ACTION
----
481
4.1.5.3
CLINICAL
TRIALS
-----
486
4.1.5.4
CLINICAL
TRIALS
-
REASONS
FOR
DATA
VARIABILITY
----
488
4.1.5.5
ACTUAL
SITUATION
-----
492
4.1.6
ASPIRIN
"
HIGH
ON
TREATMENT
PLATELET
REACTIVITY
"
(HTPR,
ASPIRIN
RESISTANCE)
-
500
4.1.6.1
GENERAL
ASPECTS
-----
500
4.1.6.2
DEFINITION
AND
TYPES
OF
ASPIRIN
-
HTPR
----
501
4.1.6.3
DETECTION
OF
ASPIRIN
HTPR
----
504
4.1.6.4
MECHANISMS
OF
ASPIRIN
HTPR
------
507
4.1.6.5
CLINICAL
TRIALS
-----
515
4.1.6.6
ACTUAL
SITUATION
-----
519
4.2
PAIN,
FEVER
AND
INFLAMMATORY
DISEASES
-----
528
4.2.1
ANALGESIA
AND
ANTIPYRESIS
-----
529
4.2.1.1
GENERAL
ASPECTS
-----
529
4.2.1.2
PAIN,
FEVER
AND
MODE
OF
ANALGESIC/ANTIPYRETIC
ASPIRIN
ACTION
----
530
4.2.1.3
CLINICAL
TRIALS
-----
534
4.2.1.4
ASPIRIN
AND
OTHER
DRUGS
-----
538
4.2.1.5
ACTUAL
SITUATION
-----
539
4.2.2
INFLAMMATORY
DISEASES
AND
VIRAL
INFECTIONS
----
542
4.2.2.1
GENERAL
ASPECTS
-----
542
4.2.2.2
RHEUMATOID
ARTHRITIS
-
PATHOPHYSIOLOGY,
MODE
OF
ASPIRIN
ACTION
AND
CLINICAL
TRIALS
-----
544
XII
-
-
CONTENTS
4.2.2.3
OSTEOARTHRITIS
-
PATHOPHYSIOLOGY,
MODE
OF
ASPIRIN
ACTION
AND
CLINICAL
TRIALS
-----
547
4.2.2.4
SYSTEMIC
INFLAMMATORY
RESPONSE
SYNDROME
(SIRS).
PATHOPHYSIOLOGY,
MODE
OF
ASPIRIN
ACTION
AND
CLINICAL
TRIALS.
SEPSIS
AND
ACUTE
RESPIRATORY
DISTRESS
SYNDROME
(ARDS)
-----
548
4.2.2.5
HIV
-
PATHOPHYSIOLOGY,
MODE
OF
ASPIRIN
ACTION
AND
CLINICAL
TRIALS
-----
552
4.2.2.6
COVID-19
AND
FLU-LIKE
CONDITIONS:
PATHOPHYSIOLOGY,
MODES
OF
ASPIRIN
ACTION
AND
CLINICAL
TRIALS
555
4.2.2.7
ASPIRIN
AND
OTHER
DRUGS
-----
559
4.2.2.8
ACTUAL
SITUATION
-----
560
4.2.3
KAWASAKI
DISEASE
------
567
4.2.3.1
GENERAL
ASPECTS
------
567
4.2.3.2
PATHOPHYSIOLOGY
AND
MODE
OF
ASPIRIN
ACTION
-----
568
4.2.3.3
CLINICAL
TRIALS
-----
569
4.2.3.4
ASPIRIN
AND
OTHER
DRUGS
-----
571
4.2.3.5
ACTUAL
SITUATION
-----
571
4.3
FURTHER
POTENTIAL
CLINICAL
INDICATIONS
------
574
4.3.1
COLORECTAL
TUMORS
(ADENOMAS,
CARCINOMAS)
------
575
4.3.1.1
GENERAL
ASPECTS
-----
575
4.3.1.2
EPIDEMIOLOGY,
ETIOLOGY
AND
PATHOGENESIS
----
576
4.3.1.3
MODES
OF
ASPIRIN
ACTION
----
578
4.3.1.4
CLINICAL
TRIALS
-
PRIMARY
PREVENTION
----
581
4.3.1.5
CLINICAL
TRIALS
-
SECONDARY
PREVENTION
----
587
4.3.1.6
ASPIRIN
AND
OTHER
DRUGS
-----
593
4.3.1.7
ACTUAL
SITUATION
-----
594
4.3.2
ALZHEIMER
'
S
DISEASE
AND
OTHER
NEUROLOGICAL
DISORDERS
----
602
4.3.
2.1 GENERAL
ASPECTS
-----
602
4.3.2.2
EPIDEMIOLOGY,
ETIOLOGY
AND
PATHOPHYSIOLOGY
-----
602
4.3.2.3
MODES
OF
ASPIRIN
ACTION
-----
603
4.3.2.4
CLINICAL
TRIALS
-----
605
4.3.2.5
ASPIRIN
AND
OTHER
DRUGS
-----
609
4.3.2.6
ACTUAL
SITUATION
-----
609
ABBREVIATIONS
----
613
ACRONYMS
OF
CLINICAL
TRIALS
-
617
INDEX
----
623 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author | Schrör, Karsten 1942- |
| author_GND | (DE-588)120284472 |
| author_facet | Schrör, Karsten 1942- |
| author_role | aut |
| author_sort | Schrör, Karsten 1942- |
| author_variant | k s ks |
| building | Verbundindex |
| bvnumber | BV048461179 |
| classification_rvk | VT 5000 |
| ctrlnum | (OCoLC)1347218212 (DE-599)DNB1250851882 |
| discipline | Chemie / Pharmazie |
| discipline_str_mv | Chemie / Pharmazie |
| edition | 3rd edition |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01839nam a2200481 c 4500</leader><controlfield tag="001">BV048461179</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20221006 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">220908s2022 a||| |||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">22,N06</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1250851882</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783110745726</subfield><subfield code="c">: EUR 159.95 (DE) (freier Preis), EUR 159.95 (AT) (freier Preis)</subfield><subfield code="9">978-3-11-074572-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1347218212</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1250851882</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-83</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VT 5000</subfield><subfield code="0">(DE-625)147738:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">540</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Schrör, Karsten</subfield><subfield code="d">1942-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)120284472</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Acetylsalicylic acid</subfield><subfield code="c">Karsten Schrör</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">3rd edition</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin</subfield><subfield code="b">De Gruyter dup</subfield><subfield code="c">[2022]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XII, 630 Seiten</subfield><subfield code="b">Illustrationen, Diagramme</subfield><subfield code="c">24 cm x 17 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakologie</subfield><subfield code="0">(DE-588)4045687-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Acetylsalicylsäure</subfield><subfield code="0">(DE-588)4000351-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Toxikologie</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Pharmakologie</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Arzneimittel</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Organische Chemie</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Drug, Organic chemistry, Pharmacology, Toxicology</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Acetylsalicylsäure</subfield><subfield code="0">(DE-588)4000351-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Pharmakologie</subfield><subfield code="0">(DE-588)4045687-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe</subfield><subfield code="z">9783110746488</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe</subfield><subfield code="z">9783110746419</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033839178&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033839178</subfield></datafield></record></collection> |
| id | DE-604.BV048461179 |
| illustrated | Illustrated |
| index_date | 2024-07-03T20:33:39Z |
| indexdate | 2024-07-10T09:38:47Z |
| institution | BVB |
| isbn | 9783110745726 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033839178 |
| oclc_num | 1347218212 |
| open_access_boolean | |
| owner | DE-83 |
| owner_facet | DE-83 |
| physical | XII, 630 Seiten Illustrationen, Diagramme 24 cm x 17 cm |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | De Gruyter dup |
| record_format | marc |
| spelling | Schrör, Karsten 1942- Verfasser (DE-588)120284472 aut Acetylsalicylic acid Karsten Schrör 3rd edition Berlin De Gruyter dup [2022] © 2022 XII, 630 Seiten Illustrationen, Diagramme 24 cm x 17 cm txt rdacontent n rdamedia nc rdacarrier Pharmakologie (DE-588)4045687-0 gnd rswk-swf Acetylsalicylsäure (DE-588)4000351-6 gnd rswk-swf Toxikologie Pharmakologie Arzneimittel Organische Chemie Drug, Organic chemistry, Pharmacology, Toxicology Acetylsalicylsäure (DE-588)4000351-6 s Pharmakologie (DE-588)4045687-0 s DE-604 Erscheint auch als Online-Ausgabe 9783110746488 Erscheint auch als Online-Ausgabe 9783110746419 DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033839178&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Schrör, Karsten 1942- Acetylsalicylic acid Pharmakologie (DE-588)4045687-0 gnd Acetylsalicylsäure (DE-588)4000351-6 gnd |
| subject_GND | (DE-588)4045687-0 (DE-588)4000351-6 |
| title | Acetylsalicylic acid |
| title_auth | Acetylsalicylic acid |
| title_exact_search | Acetylsalicylic acid |
| title_exact_search_txtP | Acetylsalicylic acid |
| title_full | Acetylsalicylic acid Karsten Schrör |
| title_fullStr | Acetylsalicylic acid Karsten Schrör |
| title_full_unstemmed | Acetylsalicylic acid Karsten Schrör |
| title_short | Acetylsalicylic acid |
| title_sort | acetylsalicylic acid |
| topic | Pharmakologie (DE-588)4045687-0 gnd Acetylsalicylsäure (DE-588)4000351-6 gnd |
| topic_facet | Pharmakologie Acetylsalicylsäure |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033839178&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT schrorkarsten acetylsalicylicacid |